The company plans to bring its continuous glucose monitoring (CGM) technology to Italy beginning in March 2025. This means it plans to end its distribution relationship with Roche next month. The companies plan to continue working together during the transition period.
Roche plans to honor and fulfill all existing contractual commitments. Both companies remain committed to ensuring uninterrupted access to Dexcom One+ sensors and customer support.
Dexcom plans to establish its presence in Italy with an office in Milan. It plans to implement a direct local team of marketing, medical affairs and market access professionals. The company also intends to strengthen its long-standing collaboration with Theras as an external sales force for Dexcom One+.
The Dexcom One+ platform, Dexcom’s commercial CGM offering outside the U.S., uses the company’s established sensor design. This version of the platform utilizes the latest-generation G7 sensor, while the previous version used the G6. ONE+ also adds certain notes at certain moments, like meals, insulin administration and sports activities. The system replaces the traditional fingersticks to provide a clear picture of how daily choices affect glucose levels.
“By establishing a direct presence in Italy, I believe we will be better positioned to understand and meet the needs of healthcare providers, as well as the needs of those who rely on and use our sensors. My sincere thanks go to my colleagues at Roche for the partnership up to and during the transition, and to those at Theras for the current and future collaboration,” said Raffaele Pulvirenti, senior director of commercial operations for the Southern Europe Cluster at Dexcom. “At Dexcom, we are relentlessly focused on providing the best possible experience for users and healthcare professionals, and I am confident that this milestone in our company’s history will be able to deliver that in Italy.”
Dexcom insulin delivery partner Insulet recently expanded its presence in Europe with a rollout in Italy as well.
